Fabrice Pierre

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner et al. · Cancer Research · 2010 · 513 citations

Medicine, Oncology, Pharmacology +16

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer

Roberto Battistutta, Giorgio Cozza, Fabrice Pierre et al. · Biochemistry · 2011 · 174 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux et al. · ACS Medicinal Chemistry Letters · 2012 · 164 citations

Life Sciences, Oncology, Pharmacology +14

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Molecular and Cellular Biochemistry · 2011 · 155 citations

Medicine, Medicinal Chemistry, Pharmacology +4